Name: | ezetimibe |
---|---|
PubChem Compound ID: | 10573550 |
Molecular formula: | C24H21F2NO3 |
Molecular weight: | 409.425 g/mol |
Name: | ezetimibe |
---|---|
Name (isomeric): | DB00973 |
Drug Type: | small molecule |
Brand: | Ezetrol, Zetia, Ezedoc |
Brand name mixture: | Inegy(Simvastatin + Ezetimibe) |
Category: | Cholesterol Absorption Inhibitors, Anticholesteremic Agents |
CAS number: | 163222-33-1 |
Indication: | For use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. |
---|---|
Pharmacology: |
Ezetimibe is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. Ezetimibe, administered alone is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperchole...
show more » |
Mechanism of Action: | Ezetimibe localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. |
Protein binding: | >90% |
Biotransformation: | Hepatic, intestinal wall |
Route of elimination: | Ezetimibe is primarily metabolized in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary and renal excretion. In humans, ezetimibe is rapidly metabolized to ezetimibe-glucuronide. |
Half Life: | 22 hours |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||
---|---|---|---|---|---|
Drug interaction: |
|